The combination of AS-IV inhibited cell proliferation of CT26 and induced dose-dependent cell apoptosis, significantly reducing M2 macrophages and increasing M1 macrophages. The rat model suppressed tumor growth and reduced production of anti-inflammatory factors such as TGF-β, IL-10 and VEGF-A, and increased production of anti-inflammatory factors such as IFN-γ, IL-12 and FNO-α in tumors. Astragaloside IV has an anti-tumor effect in rat colon cancer, restoring macrophages associated with the tumor. Astragaloside IV has an anti-tumor effect in rat colon cancer by reducing macrophages associated with the tumor. Cancerous cells of the intestine CT26 and mouse model were used as a model in vitro and in vivo by subcutaneous injection of CT26 cells. The repolarizing effect in vitro AS-IV on bone marrow macrophages has also been demonstrated. In this study, we investigated the therapeutic effect of AS-IV on the CRC and examined its underlying mechanism. It is recommended to seek advice from a licensed physician before performing natural, integrative, or routine treatment. By providing the information contained in this document, we do not diagnose, treat, facilitate, or prevent any disease or condition. M1 and M2 macrophage markers, mRNA and protein expression values were analyzed after AS-IV treatment. Inflammatory factors and cytokines were found on the rat model in tumors. It is expected that combination with immunoinhibitors may become a potential innovative strategy for treatment of IGC. AS-IV may cause polarization of M2 macrophages into the M1 phenotype.